Sedative and tranquilising acupuncture in the treatment of primary insomnia with anxiety

Submission date	Recruitment status	Prospectively registered
22/05/2024	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
04/06/2024	Completed	☐ Results
Last Edited	Condition category	Individual participant data
04/06/2024	Mental and Behavioural Disorders	Record updated in last year

Plain English summary of protocol

Background and study aims

This study aimed to compare the effectiveness of sedative and tranquilising acupuncture with that of conventional medicine in the treatment of primary insomnia with anxiety to provide a novel approach to the clinical treatment of this type of insomnia.

Who can participate?

Patients aged 18-65 years with primary insomnia with anxiety

What does the study involve?

Patients were randomly divided into a treatment group and a control group. The treatment group were treated with sedative and tranquilising acupuncture, and the control group were treated with estazolam, a conventional drug. Treatment effectiveness was determined after 4 and 8 weeks of treatment.

What are the possible benefits and risks of participating?

Sedative and tranquilising acupuncture can significantly improve sleep quality in patients with primary insomnia, and it can alleviate anxiety in these patients.

Where is the study run from?

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital (China)

When is the study starting and how long is it expected to run for? January 2020 to March 2023

Who is funding the study?

- 1. Young Qihuang Scholars Cultivation Project (China)
- 2. National Traditional Chinese Medicine Innovation Backbone Talent Project (China)

Who is the main contact? Peng Bai, baipeng bp3147@163.com

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Peng Bai

ORCID ID

https://orcid.org/0009-0007-3264-7721

Contact details

No. 51 of Anwai Xiaoguan Street Chaoyang District Beijing China 100029 +86 (0)1084980281 baipeng_bp3147@163.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Clinical effects of sedative and tranquilising acupuncture in the treatment of primary insomnia with anxiety in different Traditional Chinese Medicine constitutions

Study objectives

Sedative and tranquilising acupuncture can significantly improve sleep quality and efficacy in patients with primary insomnia, and it can alleviate anxiety in these patients. Compared with the control group, the treatment group exhibited long-term efficacy.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 09/04/2020, Ethics Committee of Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital (No. 1 Jiansheng Street, Shunyi District, Beijing, 100000, China; +86 (0)1089413365; syzyjjxf2020@163.com), ref: 2020SYKY03-01

Study design

Single-centre double-blinded interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment, Efficacy

Health condition(s) or problem(s) studied

Patients with primary insomnia with anxiety

Interventions

A total of 113 patients who met the inclusion criteria were selected for this study using a convenience sampling method. The simple random sampling method was used to divide them into a treatment group using sedative and tranquilising acupuncture and a control group using estazolam, a conventional drug.

Acupuncture procedure:

Acupoint selection: Four Shencong, bilateral Shenmen and bilateral Sanyinjiao were the main acupoints.

Technique: The needle was inserted to a shallow depth at Four Shencong, to a medium depth at Shenmen and perpendicularly at Sanyinjiao. Once inserted, the needle was left for 30 minutes, with the lifting-and-thrusting method applied after every 10 minutes.

30 minutes each time, five times a week from Monday to Friday (rest on Saturday and Sunday). Ten treatments were taken as a course, and a total of two courses of treatment (4 weeks) were given.

Estazolam treatment (control group): estazolam 1 mg every night (Shandong Xinyi Pharmaceutical Co., LTD).

Efficacy was determined after 4 and 8 weeks of treatment. The statistical analysis was performed using SPSS 26.0 statistical software. The measurement data were expressed as mean ± standard deviation. Data conforming to a normal distribution were compared between the two groups using an independent sample t-test, and the within-group comparison was conducted using a paired sample t-test. Data not conforming to a normal distribution were compared using the Wilcoxon rank-sum test, and the count data were tested using a chi-square test. The difference was considered statistically significant at P < 0.05.

Intervention Type

Supplement

Primary outcome(s)

Primary insomnia assessed using the Pittsburgh Sleep Quality Index (PSQI) after 4 and 8 weeks of treatment

Key secondary outcome(s))

- 1. Anxiety states assessed using the Self-Assessment Scale (SAS) after 4 and 8 weeks of treatment
- 2. Depressive states assessed using the Self-Rating Depression Scale (SDS) after 4 and 8 weeks of treatment

Completion date

31/03/2023

Eligibility

Key inclusion criteria

- 1. Those who met the above diagnostic criteria of primary insomnia and anxiety state
- 2. Age between 18 and 65 years, with no restriction on gender
- 3. Those who have not taken other anti-insomnia and anxiety medication in the last month
- 4. Permission was obtained from the patient

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Total final enrolment

113

Key exclusion criteria

- 1. Those who did not meet the above inclusion criteria
- 2. Age <18 or >65 years, and pregnant or lactating women
- 3. Individuals with combined visceral diseases, severe diseases of the immune and blood systems, mental illnesses and recent neurological injuries such as traumatic brain injury or spinal cord injury
- 4. Skin infection at the acupoint area

Date of first enrolment

20/08/2020

Date of final enrolment

13/03/2023

Locations

Countries of recruitment

China

Study participating centre

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

No. 1 Jiansheng Street Shunyi District Beijing China 100000

Sponsor information

Organisation

Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital

ROR

https://ror.org/01qq0qd43

Funder(s)

Funder type

Other

Funder Name

Young Qihuang Scholars Cultivation Project

Funder Name

National Traditional Chinese Medicine Innovation Backbone Talent Project

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Peng Bai (baipeng_bp3147@163.com).

IPD sharing plan summary

Available on request

Study outputs

Output type

Details

Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No

Yes